Journal Article

DZNE-2026-00542

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Speech-based digital cognitive assessment for clinical trials: Detecting cognitive impairment stages and AD biomarker relations across European cohorts.

König, A. ; Tröger, J. ; Mallick, E. ; Linz, N. ; Ritchie, C. ; Gregory, S. ; Hunter, M. ; Johnson, K. ; Benavides, G. S. ; Grau-Rivera, O. ; Radoi, A. ; Porta-Mas, C. ; Köhler, S.DZNE* ; Teipel, S.DZNE* ; Hansson, O. ; Tideman, P. ; Wuestefeld, A. ; Palmqvist, S.

2026
Wiley Hoboken, NJ

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/alz.71462

Abstract: Early detection of Alzheimer's disease (AD) is critical for timely intervention as disease-modifying treatments emerge. Speech-based digital biomarkers offer scalable options for remotely capturing speech-derived functional changes associated with early cognitive decline, but validation across real-world populations remains limited.We evaluated the speech biomarker for cognition (SB-C), an automated speech-derived measure associated with cognitive status, in 736 participants across five European cohorts (Barcelonaβeta Brain Research Center's Alzheimer's at-risk cohort, European Prevention of Alzheimer's Dementia Scotland, Dementia Study of Cognitive and Biomarker Dynamics, Longitudinal Cognitive Impairment and Dementia Study, and Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably [BioFINDER-Primary Care]). Participants completed verbal learning and semantic fluency tasks via automated phone or app-based platforms. SB-C performance was compared to Mini-Mental State Examination, Clinical Dementia Rating, Preclinical Alzheimer Cognitive Composite 5, and cerebrospinal fluid amyloid beta and phosphorylated tau181 biomarker status.SB-C significantly differentiated cognitively unimpaired and impaired groups (P < 0.001), correlated with standard cognitive measures, and showed moderate-to-high area under the curve (0.56-0.82) for classifying biomarker positivity, with strongest results in BioFINDER-Primary Care.SB-C is a scalable, remote speech-derived marker associated with cognitive status and AD biomarker group differences.

Keyword(s): Humans (MeSH) ; Male (MeSH) ; Female (MeSH) ; Biomarkers: cerebrospinal fluid (MeSH) ; Cognitive Dysfunction: diagnosis (MeSH) ; Cognitive Dysfunction: cerebrospinal fluid (MeSH) ; Alzheimer Disease: diagnosis (MeSH) ; Alzheimer Disease: cerebrospinal fluid (MeSH) ; Aged (MeSH) ; Amyloid beta-Peptides: cerebrospinal fluid (MeSH) ; Europe (MeSH) ; Cohort Studies (MeSH) ; Speech (MeSH) ; Neuropsychological Tests (MeSH) ; tau Proteins: cerebrospinal fluid (MeSH) ; Aged, 80 and over (MeSH) ; Middle Aged (MeSH) ; Alzheimer's disease ; cerebrospinal fluid biomarkers ; mild cognitive impairment ; remote cognitive assessment ; speech‐based digital biomarkers ; subjective cognitive decline ; Biomarkers ; Amyloid beta-Peptides ; tau Proteins

---

Contributing Institute(s):

1. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; Essential Science Indicators ; IF >= 10 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---